
    
      A multicenter, prospective, open-label, randomized Phase II study to compare efficacy by
      measuring rates of major molecular response (MMR) at 12 months in patients with Ph+ chronic
      phase (CP) chronic myeloid leukemia (CML) randomized to receive either dasatinib 50 mg QD or
      dasatinib 100 mg QD. Approximately 100 patients are expected to be randomized. The duration
      of patient participation will be 18 months
    
  